Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.79
-1.4%
$6.25
$7.96
$24.15
$14.07M0.6316,365 shs119,062 shs
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$5.00
+0.2%
$4.40
$3.20
$28.60
$48.96M0.27423,636 shs940,825 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.11
+1.0%
$1.90
$0.77
$4.08
$291.78M1.4922,864 shs662,949 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.29
+10.5%
$8.18
$2.20
$12.78
$254.45M-0.66190,493 shs138,331 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00%-14.15%-58.36%-71.44%-83.98%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
+0.20%+0.40%+20.19%+29.53%-74.13%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
+0.96%+0.48%+8.76%-28.96%+43.54%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
+10.46%-3.23%+8.91%+121.72%+52.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
3.0512 of 5 stars
3.15.00.00.02.51.71.3
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.9919 of 5 stars
4.63.00.00.03.55.00.0
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.8302 of 5 stars
3.54.00.00.02.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
2.25
Hold$44.60792.00% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13522.04% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.00
Buy$18.5099.14% Upside

Current Analyst Ratings Breakdown

Latest BLUE, CMPX, DBVT, and ALVR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/5/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/4/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $24.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/2/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
$103.95M0.47N/AN/A$35.59 per share0.14
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K343.27N/AN/A$1.17 per share1.80
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$15.73M16.18N/AN/A$7.27 per share1.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
bluebird bio, Inc. stock logo
BLUE
bluebird bio
-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)

Latest BLUE, CMPX, DBVT, and ALVR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
bluebird bio, Inc. stock logo
BLUE
bluebird bio
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
bluebird bio, Inc. stock logo
BLUE
bluebird bio
0.37
0.51
0.33
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.22
2.22

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
87.43%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
bluebird bio, Inc. stock logo
BLUE
bluebird bio
1.40%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
bluebird bio, Inc. stock logo
BLUE
bluebird bio
5209.79 million9.59 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million20.18 millionOptionable

Recent News About These Companies

Combined General Meeting of June 11, 2025
DBV Technologies: A Great Time To Sell
Why DBV Technologies S.A. (DBVT) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.79 -0.04 (-1.41%)
As of 05/23/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

bluebird bio stock logo

bluebird bio NASDAQ:BLUE

$5.00 +0.01 (+0.20%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.00 0.00 (-0.10%)
As of 05/27/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.11 +0.02 (+0.96%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.13 +0.02 (+1.18%)
As of 05/27/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.29 +0.88 (+10.46%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$9.51 +0.22 (+2.37%)
As of 05/27/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.